688302 Hinova Pharmaceuticals Inc.
- 32.20
- -1.28-3.82%
Hinova Pharmaceuticals Inc. News
Notice on voluntary disclosure of the clinical trial of the oral PROTAC drug HP568 tablets for the treatment of ER+/HER2-advanced breast cancer to obtain the drug clinical trial approval notice
Announcement on the expiration of the holdings reduction plan for shareholders holding 5% or more of the shares and the change in equity of 1%
Haichuang Pharmaceutical Investor Relations Activity Record Form (September 2024)
Voluntary disclosure announcement on the approval of the US FDA for clinical trial application of HP515 tablets for the treatment of metabolic steatohepatitis (MASH)
CITIC Securities Co., Ltd.\'s 2024 semi-annual continuous supervision and follow-up report on Haichuang Pharmaceutical Co., Ltd.
Announcement on attending the 2024 Semi-Annual Science and Technology Innovation Board Special Group Results Briefing on Pharmaceuticals and Biological Products
Notice on voluntary disclosure of the clinical trial of HP515 tablets for the treatment of non-alcoholic steatohepatitis to obtain a drug clinical trial approval notice
Announcement of Resolution of the Fifth Meeting of the Second Board of Supervisors.
Announcement of Resolutions of the Sixth Meeting of the Second Board of Directors.
Half-year report for the year 2024.
Summary of Half-Year Report in 2024.
Special report on the use of funds raised during the first half of 2024.
Announcement of voluntary disclosure of clinical trial approval notice for drug clinical trial of HP560 tablets used for the treatment of myelofibrosis (myeloproliferative tumor)
Announcement of voluntary disclosure of the clinical phase I/II trial application for HP537 for the treatment of hematological malignancies approved by the United States FDA.
Announcement on voluntary disclosure of oral PROTAC drug HP518 intended for the treatment of androgen receptor (AR) positive triple-negative breast cancer granted Fast Track designation by the US FDA.
Investor Relations Activity Record Form of Haichuang Pharmaceutical (June 17-26, 2024)
Announcement on the plan of concentrated bidding reduction of shareholding by shareholders holding more than 5% of the shares
Announcement on voluntary disclosure of clinical data for the PROTAC drug under development HP518 to be released at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Announcement on the resignation of senior management personnel and adjustment of core technical personnel
CITIC Securities Co., Ltd.'s inspection opinion on the departure of core technicians of Haichuang Pharmaceutical Co., Ltd.
Analysis
Price Target
No Data
No Data